DYN Dyne Therapeutics, Inc.

XNAS 16.08 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DYN $16.08 —
Key stats
$16.08
52-Week Range
$14.00 – $27.30
YTD
-13.10%
IV Rank (30D)
40.76
Straddle Price
$2.45
P/C Vol Ratio
1.62
Market Cap
$3.0B
Open
$16.00
Day Range
$15.72 – $16.90
Volume
1,646,079
Prev Close
$15.87
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY1.24
Cost of Equity (CAPM)11.96% (VRP-adj)
WACC11.45%
Volatility Risk Premium+82.4pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.6B
Return on Equity (TTM)-65.0%
Book / Price32.3% — banking bias active (P/B is primary)
Debt / Equity0.21
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$16.66 (Market Anchor value)
SMA 20 / Bollinger Mid$17.07
Bollinger Width / SMA2021.4% (drives anchor stability)
Net Debt$-0.7B
Market Cap$3B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
81%
20-Day Fair Value
≈ by Dec 18, 2026
$15.89
α +0.1% rank 51%
conviction
11%
40-Day Fair Value
≈ by Jan 18, 2027
$16.04
α +1.1% rank 43%
conviction
66%
60-Day Fair Value
≈ by Feb 16, 2027
$16.25
α +2.4% rank 40%
conviction
81%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 40.2× · 3 peers
Peer EV/EBITDA n/a 0% median 19.7× · 3 peers
Peer P/B $18.18 15% median 3.5× · 3 peers
Peer P/S n/a 0% median 3.8× · 3 peers
Market Anchor (SMA50) $16.66 46% stability 60% (BB-width)
Options Expected (B-L 30d) $16.06 39% 21 strikes · skew +0.31
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$3.0B
Employees
258
List Date
2020-09-17
CIK
0001818794
Last Earnings
Nov 5 after close · +4.1% vs ±12.4% expected
Headquarters
Waltham, MA
Homepage
https://www.dyne-tx.com

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its P…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan1.68%-39.53%24.79%63.86%-44.15%-3.30%0.56%
Feb-2.74%11.01%-11.84%21.94%-1.87%-16.74%-0.04%
Mar-12.31%11.32%-15.48%-2.54%-15.10%12.26%-3.64%
Apr23.46%-21.84%-6.24%-9.61%27.74%-3.04%1.74%
May6.82%-43.54%16.76%23.42%-0.25%11.16%2.40%
Jun13.00%56.49%-12.04%12.35%-25.04%19.22%10.66%
Jul-15.80%45.69%8.56%20.91%13.48%14.79%14.60%
Aug-5.63%-7.72%-3.72%9.53%34.23%0.75%4.57%
Sep-3.96%20.15%-23.87%12.46%-6.30%-35.82%-6.22%
Oct-9.71%-9.67%-11.21%-16.97%80.64%5.50%6.43%
Nov-2.20%8.94%51.78%6.51%-9.17%-8.27%*7.93%
Dec-6.05%-2.85%18.75%-19.54%-5.09%---2.96%
Total-18.18%-20.31%14.02%158.66%-1.22%-16.58%19.40%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $17.08
SMA 50: $16.61
SMA 200: $19.28
Current: $16.05
EMA 12: $16.79
EMA 26: $16.95
MACD: -0.1571 | Signal: -0.1621
BULLISH
ADX (14): 19.64
RANGE
+DI: 19.41
−DI: 25.25

Momentum Oscillators

RSI (14): 42.62
NEUTRAL
Stoch %K: 4.49
Stoch %D: 11.63
Williams %R: -89.94

Volume & Volatility

BB Upper: $18.87
BB Lower: $15.29
NEUTRAL
OBV: 13,365,353
Vol SMA 20: 2,375,090
Vol ROC: -48.93%
ATR: $0.93
True Range: $1.18
HV 20: 56.6%
HV 30: 61.0%
HV 60: 63.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before DYN’s Nov 5 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 8/10)

Key Drivers:

  • Strong technical momentum with a bullish MACD crossover
  • Recent positive news headlines on stock offerings and clinical trial advancements
  • Low volatility regime, indicating potential for further gains

Primary Risks:

  • High beta, indicating increased market sensitivity and potential for larger price movements
  • Negative earnings or regulatory surprises could lead to significant declines

Investment Thesis: Dyne Therapeutics (DYN) presents a compelling investment opportunity due to its strong technical momentum, positive news flow, and relatively low volatility. However, investors should be aware of the high beta and potential for large price swings.

Recent News Sentiment Impact: The recent news headlines have had a predominantly positive impact on the stock's sentiment, with stories on successful public offerings and clinical trial advancements contributing to the bullish tone.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bullish
  • Medium-term (1-3 months): Bullish
  • Long-term (3-12 months): Neutral

Support/Resistance Levels: Key price levels include:

  • Lower Bollinger Band ($23.62)
  • Middle Bollinger Band ($25.48)
  • Upper Bollinger Band ($27.34)

Momentum Signals:

  • RSI Interpretation: Neutral (60.96), indicating no strong buying or selling pressure
  • MACD Signal: Bullish, with a crossover above the signal line
  • Bollinger Bands Position: Squeeze, indicating potential for a breakout

Volume Analysis: Institutional interest signals are mixed, with a relatively low volume rate of change (-38.15%) and a moderate OBV (24698332.88).

News & Sentiment Analysis

Recent Headlines Summary:

The recent news headlines have been predominantly positive, focusing on successful public offerings and clinical trial advancements.

Sentiment Assessment: Positive (65%)

Catalyst Identification: Earnings information is not currently available; however, upcoming catalysts include clinical trial results and regulatory approvals.

Market Narrative: The market narrative has shifted in favor of DYN, with positive news headlines contributing to the bullish tone. This aligns with the technical momentum signals, suggesting a potential for further gains.

Risk & Volatility Assessment

Beta Interpretation: High beta (1.92) indicates increased market sensitivity and potential for larger price movements.

Volatility Regime: Current volatility is relatively low (0.77), indicating a potentially stable environment.

Options Market Signals:

  • IV Rank: 18.8% (Low)
  • Current IV: 114.9%
  • Expected Move: $5.20 (32 DTE)
  • Volume Flow: 64 calls vs 25 puts
  • Open Interest: 338 calls vs 40 puts

Market Context & Positioning

Sector Performance: DYN is performing relatively well within the healthcare sector.

Institutional Activity: Mixed signals from institutional interest, with a moderate OBV and low volume rate of change.

Correlation Analysis: R-squared interpretation suggests that DYN moves more independently than the market (0.32).

Relative Valuation: DYN is positioned near its upper Bollinger Band ($27.34), indicating potential for further gains or consolidation.

Key Levels & Action Items

Critical Price Levels:

  • Lower Bollinger Band ($23.62)
  • Middle Bollinger Band ($25.48)
  • Upper Bollinger Band ($27.34)

Breakout/Breakdown Levels:

  • $26.15 (current price)
  • $28.00 (psychological resistance level)

Time-Sensitive Catalysts: Earnings information and clinical trial results are upcoming catalysts.

Risk Management: Stop-loss levels should be set around the lower Bollinger Band ($23.62), with position sizing considerations based on individual risk tolerance.

Generated
Earnings History
18 of 18 under expected move
Avg Expected Move
23.10%
Avg Actual Move
6.49%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-05-06 Pre-Market 11.24% 1.80% 0.16x Within
2023-05-11 Pre-Market 23.08% 2.82% 0.12x Within
2023-08-03 Pre-Market 11.90% 2.21% 0.19x Within
2023-10-30 Pre-Market 74.77% 10.57% 0.14x Within
2024-03-05 Pre-Market 15.45% 6.64% 0.43x Within
2024-05-02 Pre-Market 10.84% 0.66% 0.06x Within
2024-08-12 Pre-Market 12.61% 1.22% 0.10x Within
2024-11-12 Pre-Market 13.69% 4.27% 0.31x Within
2025-01-10 Pre-Market 39.37% 32.85% 0.83x Within
2025-02-27 Pre-Market 21.39% 4.50% 0.21x Within
2025-05-08 Pre-Market 23.67% 20.16% 0.85x Within
2025-07-28 After-Close 17.99% 1.18% 0.07x Within
2025-11-05 Pre-Market 18.24% 2.88% 0.16x Within
2026-01-12 Pre-Market 14.07% 1.74% 0.12x Within
2026-03-02 After-Close 62.54% 9.60% 0.15x Within
2026-05-11 Pre-Market 13.06% 4.83% 0.37x Within
2026-07-27 Pre-Market 19.44% 4.87% 0.25x Within
2026-11-05 After-Close 12.38% 4.09% 0.33x Within

Earnings calendar: this week’s reports with expected vs actual moves →

DYN Options Activity & IV Rank

DYN IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 73.4%
7-DTE IV: —
Expected Move: $2.45
7-DTE Move: $1.17
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 3,444
Put Volume: 5,579
P/C Volume: 1.62
BEARISH
Call OI: 95,307
Put OI: 14,373
P/C OI: 0.151
Total OI: 109,680

ATM Options Pricing

ATM Call: $1.27
ATM Put: $1.18
Call %: 7.9%
Put %: 7.3%

Chain Summary

Chain Volume: 9,023
Chain OI: 109,680
Last Updated: 11/19/2026

DYN Implied Volatility

30-day IV
73.4%
Nov 19
IV rank
41Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much DYN actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 89th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
89%
vs own history
GEX tilt
+0.90
OI-weighted, today
Vanna tilt
+0.86
δ-sensitivity to IV
Charm tilt
-0.96
δ-decay vs time
Vanna tilt +0.86: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.96: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 24 ATM contracts, 25k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 68.0% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)40.8MediumNov 19

Embed DYN IV rank

DYN's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$2.45Nov 19
Beta Analysis

Risk Metrics

Beta: 1.7827
Alpha: -27.53%
Correlation: 0.3867
R-Squared: 15.0%
Stock Volatility: 63.4%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own DYN
5 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$25.4M
0.01%
#1017 of 6285+468.7%13F
Millennium Management Hedge fund
Izzy Englander
$9.6M
0.01%
#1601 of 3716+172.4%13F
Renaissance Technologies Hedge fund
Jim Simons
$2.1M
0.00%
#1928 of 3151-63.5%13F
Soros Fund Management Family office
George Soros, Robert Soros, Jonathan Soros
$322K
0.00%
#229 of 245new13F
Rockefeller Capital Management Family office
Rockefeller family
$301K
0.00%
#2435 of 4858+30.7%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

DYN Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 165,107,291 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

266 filers193,992,677 shares$3.88B value117.49% of float
# Filer Shares Value % of Total % of Float Period
1 T. Rowe Price Investment Management, Inc. 30,912,287 $686.56M 17.67% 18.72% 2026-06-30
2 Jupiter Topco LLC 11,997,738 $266.63M 6.86% 7.27% 2026-06-30
3 FMR LLC Custodian 11,207,000 $248.91M 6.41% 6.79% 2026-06-30
4 BlackRock, Inc. Custodian 14,471,562 $233.14M 6.00% 8.76% 2026-09-30
5 Orbis Allan Gray Ltd 7,006,542 $155.62M 4.01% 4.24% 2026-06-30
6 State Street Corp 8,158,310 $131.43M 3.38% 4.94% 2026-09-30
7 Vanguard Capital Management LLC 7,552,313 $121.67M 3.13% 4.57% 2026-09-30
8 TCG Crossover Management, LLC 4,615,144 $102.50M 2.64% 2.80% 2026-06-30
9 T. Rowe Price Associates, Inc. 3,936,806 $87.44M 2.25% 2.38% 2026-06-30
10 FCPM III SERVICES B.V. 3,848,256 $85.47M 2.20% 2.33% 2026-06-30
11 Vanguard Portfolio Management LLC 4,691,667 $75.58M 1.95% 2.84% 2026-09-30
12 Vestal Point Capital, LP 3,375,000 $74.96M 1.93% 2.04% 2026-06-30
13 ORBIMED ADVISORS LLC 3,235,684 $71.86M 1.85% 1.96% 2026-06-30
14 Geode Capital Management, LLC Custodian 4,396,372 $70.84M 1.82% 2.66% 2026-09-30
15 Frazier Life Sciences Management, L.P. 3,153,082 $70.03M 1.80% 1.91% 2026-06-30
16 ARMISTICE CAPITAL, LLC 3,087,226 $68.57M 1.77% 1.87% 2026-06-30
17 PERCEPTIVE ADVISORS LLC 2,689,235 $59.73M 1.54% 1.63% 2026-06-30
18 Logos Global Management LP 2,550,000 $56.64M 1.46% 1.54% 2026-06-30
19 Atlas Venture Life Science Advisors, LLC 3,440,720 $55.43M 1.43% 2.08% 2026-09-30
20 Bank of America Corp Custodian 2,233,398 $49.60M 1.28% 1.35% 2026-06-30
21 Venrock Adviser, LLC 2,173,913 $48.28M 1.24% 1.32% 2026-06-30
22 Goldman Sachs Group Inc Custodian 2,157,195 $47.91M 1.23% 1.31% 2026-06-30
23 JPMorgan Chase & Co Custodian 2,912,998 $47.38M 1.22% 1.76% 2026-09-30
24 MPM BioImpact LLC 1,922,093 $42.69M 1.10% 1.16% 2026-06-30
25 Siren, L.L.C. 2,429,125 $39.13M 1.01% 1.47% 2026-09-30
7 filers$24.31M notional
# Filer Notional Value % of Total Period
1 Nantahala Capital Management, LLC $16.96M 69.76% 2026-09-30
2 Jane Street Group, LLC Custodian $5.32M 21.87% 2026-09-30
3 GROUP ONE TRADING LLC Custodian $890.88K 3.66% 2026-09-30
4 Citigroup Inc. Custodian $386.64K 1.59% 2026-09-30
5 Susquehanna International Group, LLP Custodian $330.93K 1.36% 2026-06-30
6 Citadel Advisors LLC Custodian $257.64K 1.06% 2026-06-30
7 Simplex Trading, LLC Custodian $167.54K 0.69% 2026-09-30
7 filers$6.70M notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $2.97M 44.27% 2026-09-30
2 Susquehanna International Group, LLP Custodian $1.39M 20.75% 2026-06-30
3 Caption Management, LLC $790.68K 11.80% 2026-06-30
4 Citadel Advisors LLC Custodian $708.50K 10.58% 2026-06-30
5 Simplex Trading, LLC Custodian $414.03K 6.18% 2026-09-30
6 Citigroup Inc. Custodian $386.64K 5.77% 2026-09-30
7 GROUP ONE TRADING LLC Custodian $43.50K 0.65% 2026-09-30

DYN Insider Trading (Form 4)

Latest: 2026-10-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-22 Douglas Kerr Head of R&D and CMO Award (A) +8,000 — EDGAR
2026-10-06 Brian S Posner Director Buy (P) +2,500 $16.00 $40.0K EDGAR
2026-09-08 Johanna Friedl-Naderer Chief Commercial Officer Sell (S) −1,085 $23.42 -$25.4K EDGAR
2026-09-08 John Cox CEO & President Sell (S) −5,658 $18.88 -$106.8K EDGAR
2026-09-08 Douglas Kerr Chief Medical Officer Sell (S) −5,035 $22.95 -$115.5K EDGAR
2026-08-17 Johanna Friedl-Naderer Chief Commercial Officer Sell (S) −226 $26.28 -$5.9K EDGAR
2026-08-17 Douglas Kerr Chief Medical Officer Sell (S) −1,556 $26.28 -$40.9K EDGAR
2026-08-17 Erick Lucera Chief Financial Officer Sell (S) −1,797 $26.28 -$47.2K EDGAR
2026-08-17 Jason P Rhodes Director Sell (S) −2,586,928 $25.20 -$65.18M EDGAR
2026-08-17 John Cox CEO & President Sell (S) −4,986 $26.28 -$131.0K EDGAR
2026-07-29 Dirk Kersten Director Sell (S) −261,460 $25.51 -$6.67M EDGAR
2026-07-08 Jason P Rhodes Director Sell (S) −777,451 $22.97 -$17.86M EDGAR
2026-06-26 Erick Lucera Chief Financial Officer Sell (S) −2,362 $20.37 -$48.1K EDGAR
2026-06-26 Jason P Rhodes Director Sell (S) −267,760 $21.09 -$5.65M EDGAR
2026-06-24 Dirk Kersten Director Sell (S) −263,962 $20.70 -$5.46M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DYN Insider Holdings

11 insiders · @ $15.87
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Dirk Kersten Director 3,586,796 $56.92M -$114.18M 40 2026-07-29
2 Jason P Rhodes Director 567,358 $9.00M -$148.46M 20 2026-08-17
3 John Cox CEO & President 429,507 $6.82M $1.39M 15 2026-09-08
4 Oxana Beskrovnaya Chief Scientific Officer 195,840 $3.11M -$3.50M 31 2025-03-13
5 Douglas Kerr Head of R&D and CMO 170,564 $2.71M -$325.8K 14 2026-10-22
6 Johanna Friedl-Naderer Chief Commercial Officer 152,897 $2.43M -$60.9K 13 2026-09-08
7 Richard William Scalzo SVP, Head of Finance & Admin. 122,330 $1.94M -$8.71M 35 2025-03-13
8 Erick Lucera Chief Financial Officer 119,766 $1.90M -$228.7K 6 2026-08-17
9 Catherine Stehman-Breen Director 115,713 $1.84M $0 8 2026-06-09
10 Edward Hurwitz Director 91,081 $1.45M $0 7 2026-06-09
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

DYN Board & Officers

As of SEC filings through Nov 16, 2026

Directors 10

Officers 4

Changes in the last 10 years (79)
Oct 22, 2026Douglas Kerr listed as Head of R&D and CMO (previously Chief Medical Officer) in SEC filings
Jun 22, 2026Barry E Greene became a director
Dec 22, 2025Vikram Karnani became a director
Oct 1, 2025Brian S Posner became a director
Mar 31, 2025Erick Lucera became Chief Financial Officer
Mar 17, 2025The company announced the departure of Richard William Scalzo as SVP, Head of Finance & Admin. in an SEC filing
Sep 3, 2024The company announced the departure of Susanna Gatti High as Chief Operating Officer in an SEC filing
Sep 3, 2024The company announced the departure of Jonathan McNeill as Chief Business Officer in an SEC filing
Sep 3, 2024Johanna Friedl-Naderer became Chief Commercial Officer
Sep 3, 2024Douglas Kerr became Chief Medical Officer
May 24, 2024Dirk Kersten no longer listed as a 10% owner in SEC filings
Mar 25, 2024John Cox became a director
Mar 25, 2024John Cox became CEO & President
Mar 21, 2024The company announced the departure of Joshua T Brumm from the board in an SEC filing
Mar 21, 2024The company announced the departure of Joshua T Brumm as Chief Executive Officer and President in an SEC filing
Jan 4, 2024Richard William Scalzo listed as SVP, Head of Finance & Admin. (previously Senior Vice President, Head of Finance and Administration) in SEC filings
Sep 13, 2023Jonathan McNeill listed as Chief Business Officer (previously Senior Vice President of Business Development) in SEC filings
May 25, 2023Edward Hurwitz no longer listed as a 10% owner in SEC filings
May 24, 2023The company announced the departure of Lawrence Otto Klein from the board in an SEC filing
Mar 15, 2023Richard William Scalzo listed as Senior Vice President, Head of Finance and Administration (previously Senior Vice President of Finance and Administration and Treasurer) in SEC filings
Not reported recently (21)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

DYN Proposed Insider Sales (Form 144)

Latest: 2026-11-13
Last 30d: 2 filings · $137K notice value  ·  Last 90d: 5 filings · $366K notice value · 2 unique filers

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Cox John (2, $200K) · Kerr Douglas (3, $166K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-11-13 Kerr Douglas Officer 2,604 $43.8K 2026-11-13 Stifel Nicolaus & Company Inc — EDGAR
2026-11-13 Cox John Officer 5,513 $92.8K 2026-11-13 Stifel Nicolaus & Company Inc — EDGAR
2026-09-08 Cox John Officer 5,658 $106.8K 2026-09-08 Stifel Nicolaus & Company Inc — EDGAR
2026-09-08 Kerr Douglas Officer 35 $661 2026-09-08 Stifel Nicolaus & Company Inc — EDGAR
2026-09-04 Kerr Douglas Officer 5,000 $121.7K 2026-09-04 Stifel Nicolaus & Company Inc — EDGAR
2026-08-14 Atlas Venture Opportunity Fund I, LP Shareholder 322,465 $8.37M 2026-08-14 Merrill Lynch 10b5-1 EDGAR
2026-08-14 Atlas Venture Fund XI, LP Shareholder 1,359,674 $35.30M 2026-08-14 Merrill Lynch 10b5-1 EDGAR
2026-08-14 Atlas Venture Opportunity Fund II, LP Shareholder 478,377 $12.42M 2026-08-14 Merrill Lynch 10b5-1 EDGAR
2026-08-13 Cox John Officer 4,986 $131.0K 2026-08-13 Stifel Nicolaus & Company Inc — EDGAR
2026-08-13 Lucera Erick Officer 1,797 $47.2K 2026-08-13 Stifel Nicolaus & Company Inc — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-05 Earnings results EDGAR
2026-09-29 Regulation FD disclosure · Other events EDGAR
2026-07-29 Earnings results EDGAR
2026-07-22 Material agreement · Other events EDGAR
2026-07-20 Other events EDGAR
2026-06-22 Director or officer change EDGAR
2026-06-17 Material agreement · New debt obligation EDGAR
2026-06-08 Shareholder vote results EDGAR
2026-06-03 Regulation FD disclosure · Other events EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-05 0001818794-26-000012 EDGAR
2026-07-29 0001193125-26-323639 EDGAR
ETF Holders
72 ETFs hold DYN
25 shown · $436.73M total exposure · 0.08% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.74% $71.3M $9.7B 2026-11-17
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $69.6M — 2026-10-31
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.09% $64.3M $75.0B 2026-11-17
4 VXF Vanguard Extended Market ETF Vanguard 0.04% $35.5M — 2026-10-31
5 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.02% $31.5M — 2026-10-31
6 VBR Vanguard Morningstar Small-Cap Value ETF Vanguard 0.03% $20.4M — 2026-10-31
7 SCHA Schwab U.S. Small-Cap ETF Nport 0.09% $20.0M — 2026-08-31
8 IBB iShares Biotechnology ETF iShares (BlackRock) 0.18% $19.3M $10.9B 2026-11-17
9 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.11% $15.2M $13.6B 2026-11-17
10 VTWO Vanguard Russell 2000 ETF Vanguard 0.08% $15.1M — 2026-10-31
11 DFAS Dimensional US Small Cap ETF Dimensional 0.04% $13.5M — 2026-11-17
12 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.06% $8.1M $13.5B 2026-11-17
13 TCAF T. Rowe Price Capital Appreciation Equity ETF Nport 0.11% $8.0M — 2026-06-30
14 VHT Vanguard Health Care ETF Vanguard 0.03% $7.1M — 2026-10-31
15 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.01% $6.1M — 2026-11-17
16 DFMC Dimensional US Micro Cap ETF Dimensional 0.08% $5.7M — 2026-11-17
17 SBIO ALPS Medical Breakthroughs ETF Nport 2.16% $5.2M — 2026-08-31
18 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $4.1M $93.0B 2026-11-17
19 TMSL T. Rowe Price Small-Mid Cap ETF Nport 0.12% $3.3M — 2026-06-30
20 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.57% $2.8M — 2026-11-18
21 SCHB Schwab U.S. Broad Market ETF Nport 0.01% $2.5M — 2026-08-31
22 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.01% $2.3M — 2026-11-17
23 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.03% $2.2M $6.6B 2026-11-17
24 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.08% $2.1M — 2026-07-31
25 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.11% $1.5M — 2026-10-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-3.63
TTM Revenue
$0.00
TTM Net Income
$-604.92M
TTM Op. Cash Flow
$-564.53M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$0.00$-193.55M$-1.06$-177.49M
Q2 '262026-06-30$0.00$-178.56M$-1.08$-130.29M
Q1 '262026-03-31$0.00$-120.85M$-0.73$-144.92M
Q4 '252025-12-31$0.00$-111.95M$-0.76$-111.83M
Q3 '252025-09-30$0.00$-108.04M$-0.76$-90.78M
Q2 '252025-06-30—$-110.86M$-0.97$-94.70M
Q1 '252025-03-31—$-115.36M$-1.05$-105.89M
Q4 '242024-12-31—$-89.54M$-0.88$-84.33M
Q3 '242024-09-30—$-97.12M$-0.96$-74.63M
Q2 '242024-06-30—$-65.10M$-0.70$-54.87M
Q1 '242024-03-31—$-65.65M$-0.81$-78.54M
Q4 '232023-12-31—$-66.64M$-1.09$-35.01M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-05
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.81
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-65.0%
ROA
-49.0%
Div Yield
0.00%
FCF Yield
-21.54%
Debt/Equity
0.21
Current Ratio
—
Market Cap
$2.62B
as of 2026-11-18

DYN vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.23T 43.9 +45.5% +25.2% 37
ISRG Intuitive Surgical Inc. $145.9B 49.1 +20.5% −27.7% 29
VRTX Vertex Pharmaceuticals Inc $136.0B 33.3 +10.5% +14.6% 63
NTRA Natera, Inc. Common Stock $42.0B — +37.4% +26.9% 58
BIIB Biogen Inc. Common Stock $37.2B 105.6 +2.3% +38.9% 100
RVMD Revolution Medicines, Inc. Common Stock $34.6B — — +102.0% 75
TWST Twist Bioscience Corporation Common Stoc $7.9B — +22.0% +244.6% 52
CYTK Cytokinetics Inc. $7.1B — +29.9% −16.6% 76
DYN Dyne Therapeutics, Inc. Common Stock $3.0B — — −13.2% 41
Peer median $39.6B 46.5 +22.0% +26.0% 61

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
24.38M
SI % of Float
14.02%
Days to Cover
10.81
Short Vol Ratio
43.2%
Free Float
173.84M
Float %
93.1%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-09-22